Innate Pharma Net Income

Innate Pharma's net income stands at $-86M as of December 2025. That compares with $-25M in the prior-year period — down 249.9% year over year. That is below the Healthcare sector average of $16B. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Innate Pharma reported $-86M in net income versus $-25M a year earlier — a 249.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

Innate Pharma sits lower the Healthcare benchmark ($16B) with a net income of $-86M. That is roughly 100.5% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

That compares with $-25M in the prior-year period — down 249.9% year over year. Sustained growth in net income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Innate Pharma's net income evolved across reporting periods, while the comparison chart places IPHA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.